TLSA vs MEDP vs CRL vs DOCS vs NVCR

For growth investors, Doximity, Inc.

(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate Tiziana Life Sciences Ltd (TLSA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Doximity, Inc.

(DOCS) is the cheapest at 23. 5x versus Medpace Holdings, Inc. at 28. 1x. On forward P/E, Charles River Laboratories International, Inc. is actually cheaper at 16. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 21x versus Medpace Holdings, Inc. 's 0. 79x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +159. 4%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: MEDP returned +1443% versus TLSA's -63. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tiziana Life Sciences Ltd (TLSA) is the lower-risk stock at 0.

74β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 199% more volatile than TLSA relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Doximity, Inc.

(DOCS) is pulling ahead at 20. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 21x versus Medpace Holdings, Inc. 's 0. 79x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Charles River Laboratories International, Inc. (CRL) trades at 16. 4x forward P/E versus 25. 2x for Medpace Holdings, Inc. — 8. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1443%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TLSA is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; CRL is a small-cap quality compounder stock; DOCS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.